The key difference
Contrave combines naltrexone (an opioid antagonist that reduces food reward) with bupropion (an antidepressant that suppresses appetite). It targets the brain’s reward system — making food less psychologically compelling.
Wegovy (semaglutide) is a GLP-1 receptor agonist that mimics a gut hormone to reduce appetite, slow digestion, and improve metabolic signaling. It targets the gut-brain axis — making you physically less hungry and fuller faster.
This fundamental difference means they’re suited to different patient profiles. Contrave works best when the primary driver of overeating is cravings, reward-seeking, and the psychological pull of food. Wegovy works best when the goal is maximum appetite suppression and metabolic improvement.
Contrave targets why you want to eat. Wegovy targets how much you want to eat. Different mechanisms, different patients, different outcomes.
Side-by-side comparison
| Feature | Contrave | Wegovy |
|---|---|---|
| Drug class | Naltrexone/bupropion (opioid antagonist + NDRI) | GLP-1 receptor agonist |
| Active ingredients | Naltrexone HCl 8mg / Bupropion HCl 90mg | Semaglutide 2.4mg |
| How taken | Oral tablet, twice daily | Weekly subcutaneous injection |
| FDA approved | September 2014 | June 2021 |
| Avg weight loss | 5–8% body weight (56 weeks) | ~15% body weight (68 weeks) |
| Cardiovascular benefit | Not established | FDA-approved to reduce MACE risk |
| Duration of use | Long-term (chronic) | Long-term (chronic) |
| Insurance coverage | Good; generic available | Varies; improving |
| Typical cost | moderate monthly out-of-pocket pricing | Insurance or insurance or higher out-of-pocket pricing |
| Main side effects | Nausea, constipation, headache, insomnia | Nausea, diarrhea, constipation |
| Controlled substance | No | No |
| Best for | Emotional eaters, cravings-driven weight gain | Maximum weight loss, cardiovascular protection |
When Contrave may be the right choice
- Your weight gain is driven by emotional eating or food cravings
- You have concurrent depression (bupropion has antidepressant properties)
- You strongly prefer oral medication over injections
- You are cost-sensitive (especially with the $99/month Home Delivery program or savings card)
- Your insurance requires step therapy before approving a GLP-1
- You cannot tolerate GLP-1 gastrointestinal side effects
Contrave is often underappreciated. For patients whose primary issue is the reward response to food — the pull toward snacking, the difficulty stopping once they start, the comfort-eating cycle — Contrave’s naltrexone component directly addresses that mechanism in a way GLP-1 medications do not.
When Wegovy may be the right choice
- You are seeking maximum weight loss (GLP-1s produce significantly greater results)
- You have cardiovascular risk factors or established heart disease
- You are comfortable with weekly self-injections
- Your insurance covers GLP-1 medications
Wegovy is the stronger weight loss medication by the numbers. For patients whose primary goal is the greatest possible reduction in body weight, and especially for those who need cardiovascular protection, Wegovy has the more strong clinical evidence.
Contrave addresses something GLP-1s don’t: the reward response to food. For patients who describe “emotional eating,” “stress eating,” or feeling like they “can’t stop” once they start eating certain foods, the naltrexone component in Contrave targets the brain’s opioid reward pathways. This makes it a particularly valuable tool for patients whose relationship with food is driven more by psychology than physiology.
What about using both?
Contrave and GLP-1 medications are generally not combined. There is limited data on co-administration, and both can cause nausea — combining them would likely amplify gastrointestinal side effects without clear added benefit.
However, some patients may start on Contrave and transition to a GLP-1 as part of a step therapy pathway or treatment evolution. This is a common and clinically appropriate sequence. PEAK clinicians manage these transitions, adjusting timing and dosing to ensure a smooth experience.
Our clinical perspective
PEAK prescribes both Contrave and Wegovy. The right choice depends on why you’re gaining weight, your insurance situation, and your treatment preferences.
Contrave is a strong option for patients whose eating is driven by cravings and reward seeking. The naltrexone-bupropion combination targets the psychological drivers of overeating in a way that other weight loss medications do not.
Wegovy is the better option for patients seeking maximum weight loss with the medical evidence for cardiovascular protection. Its GLP-1 mechanism produces more significant appetite suppression and metabolic improvement.
Your clinician will evaluate your eating patterns, health history, insurance coverage, and treatment goals to recommend the best starting point. And if one medication isn’t working, we can adjust.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
